Clinical Trials Browser

Phase 1/2 × ALK-positive NSCLC × 1 year × Clear all

NCT07491497 2026-04-14

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Phase 1/2 Recruiting

ALK-positive NSCLC